High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

This study is testing whether a higher-than-standard dose of a targeted lung cancer drug called furmonertinib (an EGFR inhibitor) works better for patients with non-small cell lung cancer that has spread to the brain, compared to the standard dose. **You may be eligible if...** - You are 18 or older with confirmed metastatic non-small cell lung cancer (NSCLC) - Your cancer has a specific genetic mutation in the EGFR gene (called 19del or L858R) - You have at least one measurable tumor in the brain - You are in good overall health (ECOG 0–1) with a life expectancy of at least 12 weeks - You have not previously received treatment with an EGFR-targeting drug **You may NOT be eligible if...** - Your tumor does not have the EGFR 19del or L858R mutation - You have already been treated with an EGFR inhibitor - You have significant heart or other organ function problems Talk to your doctor to see if this trial is right for you.